Vice President, Global Program Head (Dermatology, Immunology)

Location: Wilmington, Delaware, United States, or Morges, Switzerland

Company

hirify.global is a global, science-driven biopharmaceutical company developing targeted and immune-based therapies in Hematology, Oncology, and Immunology.

What you will do

• Lead global development strategy for assigned early-stage dermatology and immunology programs.
• Develop integrated product development plans covering clinical development, commercial target product profiles, and CMC/pharmaceutical development.
• Lead cross-functional teams through strategic planning and execution across clinical, regulatory, CMC, commercial, preclinical, and operational functions.
• Ensure programs are delivered on time, within budget, and to required quality standards.
• Partner with Project Management to identify, assess, mitigate, and escalate program risks.
• Contribute to therapy area strategy, resource planning, governance, and high-quality decision-making.

Requirements

• Deep expertise in translational dermatology and/or immunology.
• At least 15 years of pharmaceutical industry experience, including at least 10 years in early-development leadership roles.
• Proven experience leading lifecycle management and early-stage development programs.
• Experience delivering global regulatory submissions, including NDA, BLA, MAA, or JNDA submissions.
• Strong knowledge of end-to-end drug development, including Phase I–III clinical development, CMC, and preclinical processes.
• Excellent communication and presentation skills, including experience presenting to senior executive leadership; willingness to travel domestically and internationally as needed.

Culture & Benefits

• Work in a science-driven environment focused on advancing therapies for patients worldwide.
• Collaborate across global functions and therapy areas with an enterprise-first mindset.
• Lead inclusive, high-performing teams that emphasize accountability, ownership, and results.
• Apply current industry trends, regulatory developments, and scientific advances to active programs and R&D strategy.